Despite substantial progress in confronting the global HIV-1 epidemic since its inception in
the 1980s, better approaches for both treatment and prevention will be necessary to end the …

Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating,
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …

Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the
fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and
described, particularly in the last decade. This continually expanding array of bnAbs has …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

Summary bNAbs may offer advantages over traditional ART for both the prevention and
treatment of HIV-1 infection. In addition, bNAbs may target the latent viral reservoir. bNAb …

The design of next-generation bNAb-based combination or multispecific therapeutics for the
prevention and/or treatment of HIV-1 infection will need to leverage the complementarity of …

Current antiretroviral drug therapies do not cure HIV-1 because they do not eliminate a pool
of long-lived cells harboring immunologically silent but replication-competent proviruses …

Introduction: The currently available anti-HIV-1 drugs can control the infection but do not
eradicate the virus. Their long-term use can lead to side effects and resistance to therapy …